Skip to main content
PMC home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2006 Aug 25;96(5):932–944. doi: 10.1002/bit.21109

Purification of cell culture‐derived human influenza A virus by size‐exclusion and anion‐exchange chromatography

Bernd Kalbfuss 1,✉, Michael Wolff 1, Robert Morenweiser 2, Udo Reichl 1,3
PMCID: PMC7161795  PMID: 16937411

Abstract

A process comprising of size‐exclusion chromatography (SEC) and anion‐exchange chromatography (AEC) was investigated for downstream processing of cell culture‐derived influenza A virus. Human influenza virus A/PR/8/34 (H1N1) was propagated in serum‐free medium using MDCK cells as a host. Concentrates of the virus were prepared from clarified and inactivated cell culture supernatants by cross‐flow ultrafiltration as described before. SEC on Sepharose 4 FF resulted in average product yields of 85% based on hemagglutination (HA) activity. Productivity was maximized to 0.15 column volumes (cv) of concentrate per hour yielding a reduction in total protein and host cell DNA (hcDNA) to 35 and 34%, respectively. AEC on Sepharose Q XL was used to separate hcDNA from virus at a salt concentration of 0.65 M sodium chloride. Product yields >80% were achieved for loads >160 kHAU/mL of resin. The reduction in hcDNA was 67‐fold. Split peak elution and bimodal particle volume distributions suggested aggregation of virions. Co‐elution with hcDNA and constant amounts of hcDNA per dose indiciated association of virions to hcDNA. An overall product yield of 52% was achieved. Total protein was reduced more than 19‐fold; hcDNA more than 500‐fold by the process. Estimation of the dose volume from HA activity predicted a protein content at the limit for human vaccines. Reduction of hcDNA was found insufficient (about 500 ng per dose) requiring further optimization of AEC or additional purification steps. All operations were selected to be scalable and independent of the virus strain rendering the process suitable for vaccine production. Biotechnol. Bioeng. 2007;96:932–944. © 2006 Wiley Periodicals, Inc.

Keywords: human influenza A virus, cell culture‐derived, downstream processing, vaccine, size‐exclusion chromatography, anion‐exchange chromatography

References

  1. Amosenko FA, Svitkin YV, Popova VD, Terletskaya EN, Timofeev AV, Elbert LB, Lashkevich VA, Drozdov SG. 1991. Use of pratamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines. Vaccine 9: 207–209. [DOI] [PubMed] [Google Scholar]
  2. Bardiya N, Bae JH. 2005. Influenza vaccines: Recent advances in production technologies. Appl Microbiol Biotechnol 67: 299–305. [DOI] [PubMed] [Google Scholar]
  3. Brands R, Visser J, Medema J, Palache AM, Scharrenburg GJM. 1999. InfluvacTC: A safe Madine Darby canine kidney (MDCK) cell culture‐based influenza vaccine. Dev Biol Stand 98: 93–100. [PubMed] [Google Scholar]
  4. Cox HR, Scheer J, Aiston S, Bohnel E. 1947. The purification and concentration of influenza virus by means of alcohol precipitation. J Immunol 56: 149–166. [PubMed] [Google Scholar]
  5. Donald HB, Isaacs A. 1954. Counts of influenza virus particles. J Gen Microbiol 10: 457–464. [DOI] [PubMed] [Google Scholar]
  6. Ferreira GNM, Cabral JMS, Prazeres DMF. 2000. Studies on the batch adsorption of plasmid DNA onto anion‐exchange chromatographic supports. Biotechnology Progress 16: 416–424. [DOI] [PubMed] [Google Scholar]
  7. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21: 1776–1779. [DOI] [PubMed] [Google Scholar]
  8. Geschwender HH, Haller W, Hofschneider PH. 1969. Large‐scale preparations of virus by steric chromatography on columns of controlled pore glass. Biochimica et Biophysica Acta 190: 460–469. [DOI] [PubMed] [Google Scholar]
  9. Goerke AR, To BCS, Lee AL, Sagar SL, Konz JO. 2005. Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. Biotechnol Bioeng 91: 12–21. [DOI] [PubMed] [Google Scholar]
  10. Heyward JT, Klimas RA, Stapp MD, Obijeski JF. 1977. The rapid concentration and purification of influenza virus from allontoic fluid. Arch Virol 55: 107–119. [DOI] [PubMed] [Google Scholar]
  11. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U. 2006. Harvesting and concentration of human influenza A virus produced in serum‐free mammalian cell culture for the production of vaccines. Biotechnology and Bioengineering. Published online 18 August 2006 in Wiley InterScience (http://www.interscience.wiley.com). DOI 10.1002/bit.21139. [DOI] [PubMed] [Google Scholar]
  12. Kistner O, Barret PN, Mundt W, Reiter M, Schober‐Bendixen S, Dorner F. 1998. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16: 960–968. [DOI] [PubMed] [Google Scholar]
  13. Knipe DM, Howley PM. 2001. Fields Virology, Chapter 46: Orthomyxoviridae. Philadelphia: Lippincott Williams & Wilkins. [Google Scholar]
  14. Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS. 2001. Membrane ion‐exchange chromatography for process‐scale antibody purification. J Chromatogr A 907: 145–154. [DOI] [PubMed] [Google Scholar]
  15. Konz JO, Lee AL, Lewis JA, Sagar SL. 2005. Development of a purification process for adenovirus: Controlling virus aggregation to improve clearance of host cell DNA. Biotechnol Prog 21: 466–472. [DOI] [PubMed] [Google Scholar]
  16. Kumar AAP, Rao YUB, Joseph ALW, Mani KR, Swaminathan K. 2002. Process standardization for optimal virus recovery and removal of substrate DNA and bovine serum proteins in vero cell‐derived rabies vaccine. J Biosci Bioeng 94: 375–383. [DOI] [PubMed] [Google Scholar]
  17. Li Z, Gu Y, Gu T. 1998. Mathematical modeling and scale‐up of size‐exclusion chromatography. Biochem Eng J 2: 145–155. [Google Scholar]
  18. Loa CC, Lin TL, Wu CC, Bryan TA, Thacker HL, Hooper T, Schrader D. 2002. Purification of turkey coronavirus by sephacryl size‐exclusion chromatography. J Virol Methods 104: 187–194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nayak DP, Lehmann S, Reichl U. 2005. Downstream processing of MDCK cell‐derived equine influenza virus. J Chromatogr B 823: 75–81. [DOI] [PubMed] [Google Scholar]
  20. Oxford JS, Corcoran T, Hugentobler AL. 1981. Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. J Biol Stand 9: 483–491. [DOI] [PubMed] [Google Scholar]
  21. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. 2001. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19: 2716–2721. [DOI] [PubMed] [Google Scholar]
  22. Potschka M. 1991. Size‐exclusion chromatography of DNA and viruses: Properties of spherical asymmetric molecules in porous networks. Macromolecules 24: 5023–5039. [Google Scholar]
  23. Reimer CB, Baker RS, Newlin TE, Havens ML. 1966. Influenza virus purification with the zonal ultracentrifuge. Science 152: 1379–1381. [DOI] [PubMed] [Google Scholar]
  24. Reimer CB, Baker RS, Frank RM, Newlin TE, Cline GB, Anderson NG. 1967. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1: 1207–1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Scholtissek C. 1985. Stability of infectious influenza A viruses at low pH and elevated temperature. Vaccine 3: 215–218. [DOI] [PubMed] [Google Scholar]
  26. Segura MM, Kamen A, Trudel P, Garnier A. 2005. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90: 391–404. [DOI] [PubMed] [Google Scholar]
  27. Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, Horikawa Y, Takeda K, Honda T, Kino Y, Mizokami H, Mizuno K, Oka T, Honda K. 2002. Development of Vero cell‐derived inactivated Japanese encephalitis vaccine. Biologicals 30: 303–314. [DOI] [PubMed] [Google Scholar]
  28. Transfiguracion J, Jaalouk DE, Ghani K, Galipeau J, Kamen A. 2003. Size‐exclusion chromatography purification of high‐titer vesicular stomatitis virus G glycoprotein‐pseudotyped retrovectors for cell and gene therapy applications. Hum Gene Ther 14: 1139–1153. [DOI] [PubMed] [Google Scholar]
  29. Tree JA, Richardson C, Fooks AR, Clegg C, Looby D. 2001. Comparison of large‐scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19: 3444–3450. [DOI] [PubMed] [Google Scholar]
  30. Wickramasinghe SR, Kalbfuß B, Zimmermann A, Thom V, Reichl U. 2005. Tangential flow microfiltration and ultrafiltration for human influenza A virus: Concentration and purification. Biotechnol Bioeng 92: 199–208. [DOI] [PubMed] [Google Scholar]

Articles from Biotechnology and Bioengineering are provided here courtesy of Wiley

RESOURCES